Results 281 to 290 of about 73,633 (314)
Some of the next articles are maybe not open access.
Losartan induced fetal toxicity
The Indian Journal of Pediatrics, 2003Losartan is a specific angiotensin II receptor antagonist. Although the teratogenic effects of angiotensin converting enzyme (ACE) inhibitors are well documented there are limited reports of losartan induced fetal toxicity. The authors report a case of incomplete ossification of skull bones, transient oliguria and feed intolerance in a newborn ...
Ashwani Singhal +3 more
openaire +3 more sources
Losartan ointment relieves hypertrophic scars and keloid: A pilot study
Wound Repair and Regeneration, 2018Keloid and hypertrophic scars are two types of fibrosis caused by extracellular matrix overexpression, and angiotensin II via AT1 receptor is known to play a key role in stimulation of fibrosis.
Keshvad Hedayatyanfard +5 more
semanticscholar +1 more source
The pharmacokinetics of losartan in renal insufficiency
Journal of Hypertension, 1995To determine the effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of losartan (MK-954) and its metabolite E3174.A two-center, unblinded trial was performed in 18 patients (age range 31-63 years) with various degrees of renal function grouped according to the renal clearance of creatinine: group I, creatinine clearance > or ...
Shahnaz Shahinfar +9 more
openaire +3 more sources
Treatment of posttransplant erythrocytosis with losartan
Transplantation Proceedings, 1997POSTTRANSPLANT erythrosis (PTE) develops in 9% to 22% of renal transplant recipients.1–3 Defined as a persistently increased hematocrit (>0.51), it occures most commonly during the first 2 years posttransplant in hypertensive males with excellent allograft function.4 After reports of anemia in renal transplant recipients undergoing ACE inhibitor ...
V. Fournier +3 more
openaire +3 more sources
Losartan reverses impaired osseointegration in spontaneously hypertensive rats
Clinical Oral Implants Research, 2018OBJECTIVE Hypertension is not only associated with cardiovascular diseases but also with alterations in bone quality. Hypertension therefore might be a risk factor for osseointegration.
G. Mulinari-Santos +5 more
semanticscholar +1 more source
Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats
Xenobiotica; the fate of foreign compounds in biological systems, 20181. This study investigates the influence of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. 2. The pharmacokinetic profiles of losartan and EXP3174 of orally administered losartan (10 mg/kg) with or without pretreatment ...
Qingling Zhao +2 more
semanticscholar +1 more source
Losartan-Induced Hepatotoxicity
JAMA: The Journal of the American Medical Association, 1997To the Editor. —Losartan is an orally active, nonpeptide angiotensin II type I receptor antagonist that has been licensed for the treatment of hypertension in many countries. This new drug also produces beneficial hemodynamic effects both acutely and with long-term dosing in patients with symptomatic heart failure. 1 Adverse events related to losartan
openaire +2 more sources
American Journal of Respiratory and Critical Care Medicine, 2016
RATIONALE Obstructive sleep apnea (OSA) is common in people with hypertension, particularly resistant hypertension. Treatment with an antihypertensive agent alone is often insufficient to control hypertension in patients with OSA.
E. Thunström +3 more
semanticscholar +1 more source
RATIONALE Obstructive sleep apnea (OSA) is common in people with hypertension, particularly resistant hypertension. Treatment with an antihypertensive agent alone is often insufficient to control hypertension in patients with OSA.
E. Thunström +3 more
semanticscholar +1 more source
Losartan-Induced Hepatic Injury
Journal of Clinical Gastroenterology, 2002Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug has demonstrated that it is safe. Losartan-induced hepatic toxicity is extremely rare. We report a case of severe hepatic toxicity and fibrosis caused by losartan use, and we review four previously reported cases.
Gulsen Ozbay +7 more
openaire +3 more sources
Hyperuricemia and Gout: The Role of Losartan
The Senior Care Pharmacist, 2023Losartan is the only angiotensin II receptor blocker that has shown to significantly lower uric acid levels. The addition of or switch to losartan as an antihypertensive agent for patients with gout is recommended by clinical guidelines because of its benefit as a uricosuric agent.
openaire +2 more sources